apramycin and Gonorrhea

apramycin has been researched along with Gonorrhea* in 1 studies

Other Studies

1 other study(ies) available for apramycin and Gonorrhea

ArticleYear
Evaluation of apramycin against spectinomycin-resistant and -susceptible strains of Neisseria gonorrhoeae.
    The Journal of antimicrobial chemotherapy, 2019, 05-01, Volume: 74, Issue:5

    The emergence of Neisseria gonorrhoeae resistant to all currently available antimicrobial therapies poses a dire public health threat. New antimicrobial agents with activity against N. gonorrhoeae are urgently needed. Apramycin is an aminocyclitol aminoglycoside with broad-spectrum in vitro activity against MDR Gram-negative pathogens and Staphylococcus aureus. However, its activity against N. gonorrhoeae has not been described.. The activity spectrum of apramycin against a collection of MDR N. gonorrhoeae was assessed. Isolates tested included those susceptible and resistant to the structurally distinct aminocyclitol, spectinomycin.. The modal MICs for apramycin and spectinomycin were 16 mg/L and 32 mg/L, respectively. The epidemiological cut-off (ECOFF) for apramycin was 64 mg/L. No strains among 77 tested had an MIC above this ECOFF, suggesting very low levels of acquired apramycin resistance. In time-kill analysis, apramycin demonstrated rapid bactericidal activity comparable to that of spectinomycin.. Apramycin has broad-spectrum, rapidly bactericidal activity against N. gonorrhoeae. Future pharmacokinetic and pharmacodynamic studies will be needed to determine whether apramycin and/or apramycin derivatives hold promise as new therapeutics for N. gonorrhoeae infection.

    Topics: Anti-Bacterial Agents; Drug Resistance, Bacterial; Gonorrhea; Humans; Microbial Sensitivity Tests; Nebramycin; Neisseria gonorrhoeae; Spectinomycin

2019